Amgen (AMGN) Price Target Trimmed at Morgan Stanley as Policy Risks Ease

Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Blue-Chip Stocks with Growing Dividends.

On December 12, Morgan Stanley cut its price target for Amgen Inc. (NASDAQ:AMGN) from $329 to $304, but kept its Equal Weight rating. The firm’s 2026 biopharma outlook sounds more optimistic, noting that a lot of the policy headaches that dragged the industry down this year will finally ease up. With that out of the way, investors can start paying attention to how these companies are actually performing.

Just a few days earlier, on December 9, Amgen Inc. (NASDAQ:AMGN) announced that it’s boosting its quarterly dividend by 6%, raising it to $2.52 per share. That marks 15 years in a row of dividend increases, making it one of the most reliable income stocks.

Amgen Inc. (NASDAQ:AMGN)’s third quarter of 2025 looked strong. Revenue jumped 12% compared to last year, and volumes climbed 14%. Sixteen of its products posted double-digit growth. The company also rolled out AmgenNow, a direct-to-patient platform in the US for Repatha, its injectable that helps lower LDL cholesterol.

Management pointed out that Amgen is expanding in all four of its main therapeutic areas. Biosimilar revenue shot up over 50% year over year and now runs close to $3 billion annually. On top of that, Amgen is sticking to its plan to invest over $3 billion in US manufacturing this year, adding to the $40 billion it’s already poured in since 2017.

Amgen Inc. (NASDAQ:AMGN)is a global biotech company on a mission to create and deliver new medicines for people battling serious diseases.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.